ANGLE’s Parsortix system has the potential to deliver profound improvements in clinical and health economic outcomes in the treatment and diagnosis of various forms of cancer.”
Andrew Newland
Chief Executive


The epitope-independent Parsortix™ system enables isolation, identification and analysis of epithelial and mesenchymal CTCs
Presentation to the Sixth International Molecular Diagnostics Europe conference on 24 May 2018

Latest Videos

An introduction to the Parsortix system

Breaking news: Circulating Tumor Cell Clustering Shapes DNA Methylation to Enable Metastasis Seeding View Here